The Biosimilars LatAm – Mexico 2022 forum’s main focus is The Collaborative Approach which is priorly aimed at harmonizing the legal frameworks that are applicable to biosimilar drugs.

The goal is to seek and strengthen all prescription and access processes of these treatments in order to help the patients in the region.

Collaborative approaches in general, require a multidisciplinary effort and therefore all sessions presented during this forum, will provide you with a wide scope of the current status and efforts that have been made towards the improvement of the public health sector in Mexico and Latin America.

Topics included:

  • manufacturing
  • sustainability
  • commercial strategies
  • diversification of production and suppliers
  • innovation
  • competitiveness
  • quality and integrity of biopharma products

Who will
you meet?

 

More than:

Participants

Companies

HCPs

Patients

Academy

Investors

Institutions

Associations

Service Providers

Government Agencies

Industry Executives from Latam

From these areas:

  • Biosimilars
  • Biobetters
  • Biotechnology
  • Biotherapeutics
  • Analytical science
  • Regulatory compliance
  • Quality Control
  • Clinical immunology
  • Scientific Affairs
  • Pharmacovigilance
  • Research
  • Regulatory
  • Business Development
  • Marketing

Program at a Glance

Collaborative: Reference Authorities' Approach Towards Regulation
Pharmacovigilance: Acting to Protect Public Health
Interchangeability: from Regulatory Consensus to Scientific Facts

The best-practices and improvement overview directly from Healthcare professionals to secure the traceability of medicaments and ability to track the patient’s medical journey. Securing the ability to reacting promptly in case any adverse-effects happen and be able to change the cure knowing exactly the root of the problem

Ensuring the Quality and Integrity of Biopharmaceutical Products
Biosimilars' Adoption Commercial Measures
Procurement and Healthcare: Biosimilars Tendering
Innovation and Competitiveness in Pharmaceuticals: Biosimilars Case Study

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Full programme in the PDF Agenda

Download Agenda

Sponsors

Merck

We are a vibrant science and technology company. Science is at the heart of everything we do, it drives the discoveries we make and the technologies we create. For more than 350 years, curiosity has been driving us to deliver excellence to patients and customers – and to imagine the future.

Agilent

Agilent is a leader in life sciences, diagnostics and applied chemical markets. The company provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling customers to gain the insights they seek. Agilent’s expertise and trusted collaboration give them the highest confidence in our solutions.

Pall

Pall associates around the world are unified by a singular drive: to solve our customers’ biggest filtration, separation and purification challenges. And, in doing so, advance health, safety and environmentally responsible technologies. 

Our industry-leading technologies and solutions are at work in countless applications, safeguarding health, protecting critical operating assets, improving product quality, and minimizing emissions and waste. 

Our Life Sciences and Industrial teams bring focused expertise to a diverse range of customers across multiple industries, including biotechnology, pharmaceutical, medical, food and beverage, laboratory, microelectronics, aerospace, fuels, petrochemical, chemical, automotive and power generation .

Cytiva

Cytiva is a global provider of technologies and services that help advance and accelerate the development and production of therapeutic products. Promoting training, speed and efficiency for research and production workflows, allowing the delivery of innovative medicines to patients.

Sartorius

Terumo

We develop alliances with pharmaceutical companies, using Terumo technology to develop, manufacture and supply solutions to injectable drug delivery challenges. We pride ourselves on offering a portfolio of products and services for the pharmaceutical industry. By anticipating trends and maintaining a constant dialogue, we provide a first class customer experience.

Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

UDIBI

UDIBI is a third-party laboratory authorized by COFEPRIS to conduct biosimilarity studies. Our experience is huge analyzing therapeutic biomolecules (recombinant hormones, cytokines, fusion proteins and monoclonal antibodies). Nowadays our capabilities have expanded to antibody engineering and development of antibody-based therapeutics. During the COVID-19 pandemic we developed products for research and diagnostic, highlighting our ELISA kit UDITEST-V2G to detect anti-SARS-CoV-2 antibodies.

Photo Gallery from Previous Events

Testimonials

Previous Forums

Keep me updated